MedTrace Logo

A Study of RPT1G After Single and Multiple Doses in Healthy Adult Participants

NCT06667765 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2025-09-02

No results posted yet for this study

Summary

This is a first-in-human (FIH), randomized, double-blind, placebo-controlled, single and multiple dose study with staggered dose escalations in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

RPT1G

Dose formulation- Oral capsule

DRUG

Placebo

Dose formulation- Oral capsule

Sponsors & Collaborators

  • Remedy Plan Australia Pty. Ltd.

    collaborator INDUSTRY

  • Remedy Plan, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-18
Primary Completion
2025-05-14
Completion
2025-05-14

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06667765 on ClinicalTrials.gov